Outlook Therapeutics
$0.22
102
+$0.01+4.29% Thursday 20:00
Statistics
Day High
0.22
Day Low
0.19
52W High
3.39
52W Low
0.16
Volume
1,453,669
Avg. Volume
3,701,570
Mkt Cap
18.19M
P/E Ratio
-
Dividend Yield
-
Dividend
-
Upcoming
Earnings
14MayExpected
Expected EPS
-0.12
Actual EPS
N/A
Financials
-4,414.78%Profit Margin
Unprofitable2.83MRevenue
-124.85MNet Income
Analyst Ratings
$2.50Average Price Target
The highest estimate is 6.00.
From 3 ratings within the last 6 months. This is not an investment recommendation.
From 3 ratings within the last 6 months. This is not an investment recommendation.
Buy 33%
Hold 67%
Sell 0%
People Also Follow
This list is based on the watchlists of people on Stock Events who follow OTLK. It's not an investment recommendation.
Competitors
This list is an analysis based on recent market events. It's not an investment recommendation.
Regeneron Pharmaceuticals
REGN
Mkt Cap68.5B
Regenxbio
RGNX
Mkt Cap645.07M
Novartis
NVS
Mkt Cap237.61B
Bausch Health Companies
BHC
Mkt Cap2.62B
Abbvie
ABBV
Mkt Cap385.18B
Rogers
ROG
Mkt Cap1.57B
Pfizer
PFE
Mkt Cap140.15B
Johnson & Johnson
JNJ
Mkt Cap455.04B
GSK
GSK
Mkt Cap94.51B
About
Outlook Therapeutics, Inc., a late clinical-stage biopharmaceutical company, focuses on developing and commercializing monoclonal antibodies for various ophthalmic indications. Its lead product candidate is ONS-5010, an ophthalmic formulation of bevacizumab product candidate that is in Phase-III clinical trial for the treatment of wet age-related macular degeneration and other retina diseases. Outlook Therapeutics, Inc. has collaboration and license agreements with IPCA Laboratories Limited; Laboratorios Liomont, S.A. de C.V.; BioLexis Pte. Ltd.; and Zhejiang Huahai Pharmaceutical Co., Ltd. The company was formerly known as Oncobiologics, Inc. and changed its name to Outlook Therapeutics, Inc. in November 2018. Outlook Therapeutics, Inc. was incorporated in 2010 and is based in Iselin, New Jersey.
Show more...
CEO
Mr. Lawrence A. Kenyon CPA
Employees
23
Country
US
ISIN
US69012T3059
Listings
0 Comments
Share your thoughts
FAQ
What is Outlook Therapeutics stock price today?▼
The current price of OTLK is $0.22 USD — it has increased by +4.29% in the past 24 hours. Watch Outlook Therapeutics stock price performance more closely on the chart.
What is Outlook Therapeutics stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on exchange Outlook Therapeutics stocks are traded under the ticker OTLK.
Is Outlook Therapeutics stock price growing?▼
OTLK stock has risen by +5.24% compared to the previous week, the month change is a -49.28% fall, over the last year Outlook Therapeutics has showed a -81.75% decrease.
What is Outlook Therapeutics market cap?▼
Today Outlook Therapeutics has the market capitalization of 18.19M
When is the next Outlook Therapeutics earnings date?▼
Outlook Therapeutics is going to release the next earnings report on May 14, 2026.
What were Outlook Therapeutics earnings last quarter?▼
OTLK earnings for the last quarter are -0.22 USD per share, whereas the estimation was -0.23 USD resulting in a +2.94% surprise. The estimated earnings for the next quarter are N/A USD per share.
What is Outlook Therapeutics revenue for the last year?▼
Outlook Therapeutics revenue for the last year amounts to 2.83M USD.
What is Outlook Therapeutics net income for the last year?▼
OTLK net income for the last year is -124.85M USD.
How many employees does Outlook Therapeutics have?▼
As of April 05, 2026, the company has 23 employees.
In which sector is Outlook Therapeutics located?▼
Outlook Therapeutics operates in the Health Care sector.
When did Outlook Therapeutics complete a stock split?▼
The last stock split for Outlook Therapeutics was on March 14, 2024 with a ratio of 1:20.
Where is Outlook Therapeutics headquartered?▼
Outlook Therapeutics is headquartered in Iselin, US.